Efficacy and Safety of Ripretinib in Chinese Patients with Advanced Gastrointestinal Stromal Tumors as a Fourth- or Later-Line Therapy: A Multicenter, Single-Arm, Open-Label Phase II Study

PURPOSE: This is a phase II multicenter, single-arm, open-label study assessing the efficacy, safety, and pharmacokinetics (PK) of ripretinib in Chinese patients with advanced gastrointestinal stromal tumor (GIST) as a fourth- or later-line therapy. It was designed to show consistency with the phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jian, Cai, Shirong, Zhou, Yongjian, Zhang, Jun, Zhou, Ye, Cao, Hui, Wu, Xin, Deng, Yanhong, Huang, Zhao, Dong, Juan, Shen, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662900/
https://www.ncbi.nlm.nih.gov/pubmed/35686969
http://dx.doi.org/10.1158/1078-0432.CCR-22-0196

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9662900/
https://www.ncbi.nlm.nih.gov/pubmed/35686969
http://dx.doi.org/10.1158/1078-0432.CCR-22-0196

Ejemplares similares